Skip to main content

BIO-PATH HOLDINGS, INC.

corporate_fare Company Profile

BIO-PATH HOLDINGS, INC.

BPTH·OTC·Life Sciences·CIK 0001133818

We are a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company. We use a novel technology for systemic delivery to achieve target-specific protein inhibition for any gene product over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, a deoxyribonucleic acid (DNA) backbone modification. This modification is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, and it is incorporated inside a lipid bilayer with a neutral charge. This combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize® delivered antisense drug substances are systemically distributed throughout the body to reduce or eliminate target proteins in blood diseases and solid tumors. Our DNAbilize® drug candidates have demonstrated an excellent safety profile in numerous animal studies and clinical trials. DNAbilize® is a registered trademark of the Company. We currently have four drug candidates in development using DNAbilize® as a platform, targeting at least five different cancer disease indications. Our lead drug candidate, BP1001, also known as prexigebersen, is being developed to target growth factor receptor-bound protein 2 ("Grb2"). It initially began the efficacy portion of a Phase 2 clinical trial for untreated acute myeloid leukemia ("AML") patients in combination with low-dose cytarabine ("LDAC"). This combination treatment has been replaced with prexigebersen and decitabine due to changes in AML treatment.

BIO-PATH HOLDINGS, INC. (OTC:BPTH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for BPTH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-16, rated 9/10. Across its 7 most recent items scored 7 or higher, the top rating is 10/10, with 7 rated 8 or above. Recent SEC coverage for BPTH spans 8-K, 10-Q, 1-Z.

Recent high-impact activity:

  • Bio-Path Holdings Pivots to Crypto, Creates New Preferred Stock, and Restarts AML Trials
  • Distressed Biotech Pivots to Crypto, Secures Potential $10M Judgment, Cancels Reverse Split
  • BIO-PATH Holdings Discloses Going Concern, Ineffective Controls, and Massive Dilution to CEO's Advisory Firm
  • Bio-Path Holdings Amends Charter for New Preferred Stock with 51% Voting Power, Appoints Scientific Advisors
  • BIO-PATH Holdings Fails to Sell Any Shares in Regulation A Offering, Securing Zero Proceeds

Financial Snapshot

Fiscal year ended December 31, 2024
Net Income
-$9.89M
Diluted EPS
-$4.12
Op. Cash Flow
-$10.57M
Operating Income
-$11.99M
Cash & Equivalents
$1.17M
Debt / Equity
0.00×
Shares Outstanding
5.77M sh
Source: 10-K · filed 2025-03-27 · accession 0001558370-25-003837

Short Interest & Short Volume

1.86 days to cover

FINRA reported short interest of 2,365 shares in BPTH as of the October 30, 2026 settlement, unchanged from the prior period — about 1.9 days to cover at its recent average daily volume.

Short interest (bi-monthly positions)2,365 shares as of October 30, 2026
Change vs prior period 0.0%
Days to cover1.86 at avg daily volume of 1,271

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

No longer listed

BPTH (BIO-PATH HOLDINGS, INC.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed BPTH - Latest Insights

BPTH
Jul 16, 2026, 1:56 PM EDT
Filing Type: 8-K
Importance Score:
9
BPTH
May 26, 2026, 2:46 PM EDT
Filing Type: 8-K
Importance Score:
9
BPTH
May 20, 2026, 4:42 PM EDT
Filing Type: 10-Q
Importance Score:
10
BPTH
Mar 19, 2026, 9:30 PM EDT
Filing Type: 8-K
Importance Score:
9
BPTH
Feb 25, 2026, 4:44 PM EST
Filing Type: 1-Z
Importance Score:
9
BPTH
Feb 24, 2026, 2:54 PM EST
Filing Type: 8-K
Importance Score:
8
BPTH
Jan 13, 2026, 11:47 AM EST
Filing Type: 10-Q
Importance Score:
10
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets